- Investing.com
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
Metrics to compare | 068270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship068270PeersSector | |
---|---|---|---|---|
P/E Ratio | 77.7x | 16.5x | −0.5x | |
PEG Ratio | −1.71 | 0.03 | 0.00 | |
Price/Book | 1.9x | 1.6x | 2.6x | |
Price / LTM Sales | 9.2x | 4.2x | 2.9x | |
Upside (Analyst Target) | 49.4% | 23.8% | 49.4% | |
Fair Value Upside | Unlock | 13.3% | 8.2% | Unlock |